Molecular Therapy-Nucleic Acids-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=908092, encodeId=1e679080927e, content=审稿速度:2.0 经验分享：under review快两个月了，变了其次日期，都是under review，唉，不知道什么情况……还是molecular therapy转投过来的……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15ee5343096, createdName=天涯一刀, createdTime=Tue Dec 15 09:14:44 CST 2020, time=2020-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967344, encodeId=4e9396e34445, content=请问一下各位with editor 之后直接Decision in process是不是要被拒了呢？这个过程得多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5b05427874, createdName=ms2000000326068890, createdTime=Thu May 20 23:33:34 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890776, encodeId=9fc9890e769e, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：7月份投的Molecular Therapy ，编辑说研究偏向基因治疗，建议改投姊妹杂志MTNA，于是改投。中间一次小修，今天收到通知接收！比较顺利，做的比较全，机制，在体验证都做了，审稿人比较认可，小修了一些小问题。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/27/c46a23a4fdf73ffb670608d86a933046.jpg, createdBy=cfaa1692461, createdName=SCI hunter , createdTime=Fri Oct 09 12:40:14 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001862, encodeId=8b61100186282, content=一审四个月，建议大修。但是没有审稿人意见，这是什么操作？只有两条主编的意见，让我改改格式和图片。。。。这是大修？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a85e5091452, createdName=145d4029m98暂无昵称, createdTime=Thu Jul 22 23:23:31 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063270, encodeId=398010632e0d7, content=被吉大一院列为水刊了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0b1654103, createdName=wy-liang, createdTime=Sat Oct 23 22:23:01 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073649, encodeId=733910e3649c4, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：RNA结合蛋白;肿瘤 经验分享：oncogene被秒拒。cancer letters一审后建议转投translational oncology。7月初投，8月13给大修，10月14返修回去，11月15日预接受。至今状态未变。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=849f6144073, createdName=ms4000001342707312, createdTime=Wed Nov 24 21:53:41 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806467, encodeId=e20a80646e29, content=with editor40天了！急死了啊！请问大家最近有状态更新吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56d35399259, createdName=生活减法, createdTime=Thu Aug 06 10:37:17 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900023, encodeId=6be9900023fa, content=请问各位大佬，这本杂志一审一般多久啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7042270125, createdName=medscholar_49146604, createdTime=Tue Nov 17 22:54:22 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602390, encodeId=5b5f60239090, content=有没有同仁从今年二月份投稿到现在四个月了还是Under review状态的？给杂志写信也没消息😂😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/02/efd7344eb2f4c381b10c1a9b2acaf549.jpg, createdBy=22da73016, createdName=哈哈这就是学术圈, createdTime=Wed Jun 17 08:00:24 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998626, encodeId=287299862659, content=应邀审稿本国一篇，感觉质量不太高，4，5分水平吧。达不到此刊物水准，正在考虑要不拒掉，又同情本国作者，毕竟工作量不少，可能最终建议大修。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Sun Jul 11 21:27:31 CST 2021, time=2021-07-11, status=1, ipAttribution=)]

2020-12-15 天涯一刀

审稿速度:2.0
经验分享：under review快两个月了，变了其次日期，都是under review，唉，不知道什么情况……还是molecular therapy转投过来的……

116 17

展开17条回复

[GetPortalCommentsPageByObjectIdResponse(id=908092, encodeId=1e679080927e, content=审稿速度:2.0 经验分享：under review快两个月了，变了其次日期，都是under review，唉，不知道什么情况……还是molecular therapy转投过来的……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15ee5343096, createdName=天涯一刀, createdTime=Tue Dec 15 09:14:44 CST 2020, time=2020-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967344, encodeId=4e9396e34445, content=请问一下各位with editor 之后直接Decision in process是不是要被拒了呢？这个过程得多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5b05427874, createdName=ms2000000326068890, createdTime=Thu May 20 23:33:34 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890776, encodeId=9fc9890e769e, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：7月份投的Molecular Therapy ，编辑说研究偏向基因治疗，建议改投姊妹杂志MTNA，于是改投。中间一次小修，今天收到通知接收！比较顺利，做的比较全，机制，在体验证都做了，审稿人比较认可，小修了一些小问题。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/27/c46a23a4fdf73ffb670608d86a933046.jpg, createdBy=cfaa1692461, createdName=SCI hunter , createdTime=Fri Oct 09 12:40:14 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001862, encodeId=8b61100186282, content=一审四个月，建议大修。但是没有审稿人意见，这是什么操作？只有两条主编的意见，让我改改格式和图片。。。。这是大修？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a85e5091452, createdName=145d4029m98暂无昵称, createdTime=Thu Jul 22 23:23:31 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063270, encodeId=398010632e0d7, content=被吉大一院列为水刊了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0b1654103, createdName=wy-liang, createdTime=Sat Oct 23 22:23:01 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073649, encodeId=733910e3649c4, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：RNA结合蛋白;肿瘤 经验分享：oncogene被秒拒。cancer letters一审后建议转投translational oncology。7月初投，8月13给大修，10月14返修回去，11月15日预接受。至今状态未变。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=849f6144073, createdName=ms4000001342707312, createdTime=Wed Nov 24 21:53:41 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806467, encodeId=e20a80646e29, content=with editor40天了！急死了啊！请问大家最近有状态更新吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56d35399259, createdName=生活减法, createdTime=Thu Aug 06 10:37:17 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900023, encodeId=6be9900023fa, content=请问各位大佬，这本杂志一审一般多久啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7042270125, createdName=medscholar_49146604, createdTime=Tue Nov 17 22:54:22 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602390, encodeId=5b5f60239090, content=有没有同仁从今年二月份投稿到现在四个月了还是Under review状态的？给杂志写信也没消息😂😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/02/efd7344eb2f4c381b10c1a9b2acaf549.jpg, createdBy=22da73016, createdName=哈哈这就是学术圈, createdTime=Wed Jun 17 08:00:24 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998626, encodeId=287299862659, content=应邀审稿本国一篇，感觉质量不太高，4，5分水平吧。达不到此刊物水准，正在考虑要不拒掉，又同情本国作者，毕竟工作量不少，可能最终建议大修。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Sun Jul 11 21:27:31 CST 2021, time=2021-07-11, status=1, ipAttribution=)]

2021-05-20 ms2000000326068890

请问一下各位with editor 之后直接Decision in process是不是要被拒了呢？这个过程得多久呢？

55 13

展开13条回复

[GetPortalCommentsPageByObjectIdResponse(id=908092, encodeId=1e679080927e, content=审稿速度:2.0 经验分享：under review快两个月了，变了其次日期，都是under review，唉，不知道什么情况……还是molecular therapy转投过来的……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15ee5343096, createdName=天涯一刀, createdTime=Tue Dec 15 09:14:44 CST 2020, time=2020-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967344, encodeId=4e9396e34445, content=请问一下各位with editor 之后直接Decision in process是不是要被拒了呢？这个过程得多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5b05427874, createdName=ms2000000326068890, createdTime=Thu May 20 23:33:34 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890776, encodeId=9fc9890e769e, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：7月份投的Molecular Therapy ，编辑说研究偏向基因治疗，建议改投姊妹杂志MTNA，于是改投。中间一次小修，今天收到通知接收！比较顺利，做的比较全，机制，在体验证都做了，审稿人比较认可，小修了一些小问题。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/27/c46a23a4fdf73ffb670608d86a933046.jpg, createdBy=cfaa1692461, createdName=SCI hunter , createdTime=Fri Oct 09 12:40:14 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001862, encodeId=8b61100186282, content=一审四个月，建议大修。但是没有审稿人意见，这是什么操作？只有两条主编的意见，让我改改格式和图片。。。。这是大修？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a85e5091452, createdName=145d4029m98暂无昵称, createdTime=Thu Jul 22 23:23:31 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063270, encodeId=398010632e0d7, content=被吉大一院列为水刊了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0b1654103, createdName=wy-liang, createdTime=Sat Oct 23 22:23:01 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073649, encodeId=733910e3649c4, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：RNA结合蛋白;肿瘤 经验分享：oncogene被秒拒。cancer letters一审后建议转投translational oncology。7月初投，8月13给大修，10月14返修回去，11月15日预接受。至今状态未变。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=849f6144073, createdName=ms4000001342707312, createdTime=Wed Nov 24 21:53:41 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806467, encodeId=e20a80646e29, content=with editor40天了！急死了啊！请问大家最近有状态更新吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56d35399259, createdName=生活减法, createdTime=Thu Aug 06 10:37:17 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900023, encodeId=6be9900023fa, content=请问各位大佬，这本杂志一审一般多久啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7042270125, createdName=medscholar_49146604, createdTime=Tue Nov 17 22:54:22 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602390, encodeId=5b5f60239090, content=有没有同仁从今年二月份投稿到现在四个月了还是Under review状态的？给杂志写信也没消息😂😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/02/efd7344eb2f4c381b10c1a9b2acaf549.jpg, createdBy=22da73016, createdName=哈哈这就是学术圈, createdTime=Wed Jun 17 08:00:24 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998626, encodeId=287299862659, content=应邀审稿本国一篇，感觉质量不太高，4，5分水平吧。达不到此刊物水准，正在考虑要不拒掉，又同情本国作者，毕竟工作量不少，可能最终建议大修。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Sun Jul 11 21:27:31 CST 2021, time=2021-07-11, status=1, ipAttribution=)]

2020-10-09 SCI hunter

审稿速度:2.0 | 投稿命中率:50.0
经验分享：7月份投的Molecular Therapy ，编辑说研究偏向基因治疗，建议改投姊妹杂志MTNA，于是改投。中间一次小修，今天收到通知接收！比较顺利，做的比较全，机制，在体验证都做了，审稿人比较认可，小修了一些小问题。

165 12

展开12条回复

[GetPortalCommentsPageByObjectIdResponse(id=908092, encodeId=1e679080927e, content=审稿速度:2.0 经验分享：under review快两个月了，变了其次日期，都是under review，唉，不知道什么情况……还是molecular therapy转投过来的……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15ee5343096, createdName=天涯一刀, createdTime=Tue Dec 15 09:14:44 CST 2020, time=2020-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967344, encodeId=4e9396e34445, content=请问一下各位with editor 之后直接Decision in process是不是要被拒了呢？这个过程得多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5b05427874, createdName=ms2000000326068890, createdTime=Thu May 20 23:33:34 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890776, encodeId=9fc9890e769e, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：7月份投的Molecular Therapy ，编辑说研究偏向基因治疗，建议改投姊妹杂志MTNA，于是改投。中间一次小修，今天收到通知接收！比较顺利，做的比较全，机制，在体验证都做了，审稿人比较认可，小修了一些小问题。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/27/c46a23a4fdf73ffb670608d86a933046.jpg, createdBy=cfaa1692461, createdName=SCI hunter , createdTime=Fri Oct 09 12:40:14 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001862, encodeId=8b61100186282, content=一审四个月，建议大修。但是没有审稿人意见，这是什么操作？只有两条主编的意见，让我改改格式和图片。。。。这是大修？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a85e5091452, createdName=145d4029m98暂无昵称, createdTime=Thu Jul 22 23:23:31 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063270, encodeId=398010632e0d7, content=被吉大一院列为水刊了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0b1654103, createdName=wy-liang, createdTime=Sat Oct 23 22:23:01 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073649, encodeId=733910e3649c4, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：RNA结合蛋白;肿瘤 经验分享：oncogene被秒拒。cancer letters一审后建议转投translational oncology。7月初投，8月13给大修，10月14返修回去，11月15日预接受。至今状态未变。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=849f6144073, createdName=ms4000001342707312, createdTime=Wed Nov 24 21:53:41 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806467, encodeId=e20a80646e29, content=with editor40天了！急死了啊！请问大家最近有状态更新吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56d35399259, createdName=生活减法, createdTime=Thu Aug 06 10:37:17 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900023, encodeId=6be9900023fa, content=请问各位大佬，这本杂志一审一般多久啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7042270125, createdName=medscholar_49146604, createdTime=Tue Nov 17 22:54:22 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602390, encodeId=5b5f60239090, content=有没有同仁从今年二月份投稿到现在四个月了还是Under review状态的？给杂志写信也没消息😂😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/02/efd7344eb2f4c381b10c1a9b2acaf549.jpg, createdBy=22da73016, createdName=哈哈这就是学术圈, createdTime=Wed Jun 17 08:00:24 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998626, encodeId=287299862659, content=应邀审稿本国一篇，感觉质量不太高，4，5分水平吧。达不到此刊物水准，正在考虑要不拒掉，又同情本国作者，毕竟工作量不少，可能最终建议大修。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Sun Jul 11 21:27:31 CST 2021, time=2021-07-11, status=1, ipAttribution=)]

2021-07-22 145d4029m98暂无昵称

一审四个月，建议大修。但是没有审稿人意见，这是什么操作？只有两条主编的意见，让我改改格式和图片。。。。这是大修？

46 11

展开11条回复

[GetPortalCommentsPageByObjectIdResponse(id=908092, encodeId=1e679080927e, content=审稿速度:2.0 经验分享：under review快两个月了，变了其次日期，都是under review，唉，不知道什么情况……还是molecular therapy转投过来的……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15ee5343096, createdName=天涯一刀, createdTime=Tue Dec 15 09:14:44 CST 2020, time=2020-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967344, encodeId=4e9396e34445, content=请问一下各位with editor 之后直接Decision in process是不是要被拒了呢？这个过程得多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5b05427874, createdName=ms2000000326068890, createdTime=Thu May 20 23:33:34 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890776, encodeId=9fc9890e769e, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：7月份投的Molecular Therapy ，编辑说研究偏向基因治疗，建议改投姊妹杂志MTNA，于是改投。中间一次小修，今天收到通知接收！比较顺利，做的比较全，机制，在体验证都做了，审稿人比较认可，小修了一些小问题。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/27/c46a23a4fdf73ffb670608d86a933046.jpg, createdBy=cfaa1692461, createdName=SCI hunter , createdTime=Fri Oct 09 12:40:14 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001862, encodeId=8b61100186282, content=一审四个月，建议大修。但是没有审稿人意见，这是什么操作？只有两条主编的意见，让我改改格式和图片。。。。这是大修？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a85e5091452, createdName=145d4029m98暂无昵称, createdTime=Thu Jul 22 23:23:31 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063270, encodeId=398010632e0d7, content=被吉大一院列为水刊了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0b1654103, createdName=wy-liang, createdTime=Sat Oct 23 22:23:01 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073649, encodeId=733910e3649c4, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：RNA结合蛋白;肿瘤 经验分享：oncogene被秒拒。cancer letters一审后建议转投translational oncology。7月初投，8月13给大修，10月14返修回去，11月15日预接受。至今状态未变。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=849f6144073, createdName=ms4000001342707312, createdTime=Wed Nov 24 21:53:41 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806467, encodeId=e20a80646e29, content=with editor40天了！急死了啊！请问大家最近有状态更新吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56d35399259, createdName=生活减法, createdTime=Thu Aug 06 10:37:17 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900023, encodeId=6be9900023fa, content=请问各位大佬，这本杂志一审一般多久啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7042270125, createdName=medscholar_49146604, createdTime=Tue Nov 17 22:54:22 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602390, encodeId=5b5f60239090, content=有没有同仁从今年二月份投稿到现在四个月了还是Under review状态的？给杂志写信也没消息😂😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/02/efd7344eb2f4c381b10c1a9b2acaf549.jpg, createdBy=22da73016, createdName=哈哈这就是学术圈, createdTime=Wed Jun 17 08:00:24 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998626, encodeId=287299862659, content=应邀审稿本国一篇，感觉质量不太高，4，5分水平吧。达不到此刊物水准，正在考虑要不拒掉，又同情本国作者，毕竟工作量不少，可能最终建议大修。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Sun Jul 11 21:27:31 CST 2021, time=2021-07-11, status=1, ipAttribution=)]

2021-10-23 wy-liang

被吉大一院列为水刊了

65 10

展开10条回复

[GetPortalCommentsPageByObjectIdResponse(id=908092, encodeId=1e679080927e, content=审稿速度:2.0 经验分享：under review快两个月了，变了其次日期，都是under review，唉，不知道什么情况……还是molecular therapy转投过来的……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15ee5343096, createdName=天涯一刀, createdTime=Tue Dec 15 09:14:44 CST 2020, time=2020-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967344, encodeId=4e9396e34445, content=请问一下各位with editor 之后直接Decision in process是不是要被拒了呢？这个过程得多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5b05427874, createdName=ms2000000326068890, createdTime=Thu May 20 23:33:34 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890776, encodeId=9fc9890e769e, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：7月份投的Molecular Therapy ，编辑说研究偏向基因治疗，建议改投姊妹杂志MTNA，于是改投。中间一次小修，今天收到通知接收！比较顺利，做的比较全，机制，在体验证都做了，审稿人比较认可，小修了一些小问题。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/27/c46a23a4fdf73ffb670608d86a933046.jpg, createdBy=cfaa1692461, createdName=SCI hunter , createdTime=Fri Oct 09 12:40:14 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001862, encodeId=8b61100186282, content=一审四个月，建议大修。但是没有审稿人意见，这是什么操作？只有两条主编的意见，让我改改格式和图片。。。。这是大修？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a85e5091452, createdName=145d4029m98暂无昵称, createdTime=Thu Jul 22 23:23:31 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063270, encodeId=398010632e0d7, content=被吉大一院列为水刊了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0b1654103, createdName=wy-liang, createdTime=Sat Oct 23 22:23:01 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073649, encodeId=733910e3649c4, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：RNA结合蛋白;肿瘤 经验分享：oncogene被秒拒。cancer letters一审后建议转投translational oncology。7月初投，8月13给大修，10月14返修回去，11月15日预接受。至今状态未变。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=849f6144073, createdName=ms4000001342707312, createdTime=Wed Nov 24 21:53:41 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806467, encodeId=e20a80646e29, content=with editor40天了！急死了啊！请问大家最近有状态更新吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56d35399259, createdName=生活减法, createdTime=Thu Aug 06 10:37:17 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900023, encodeId=6be9900023fa, content=请问各位大佬，这本杂志一审一般多久啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7042270125, createdName=medscholar_49146604, createdTime=Tue Nov 17 22:54:22 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602390, encodeId=5b5f60239090, content=有没有同仁从今年二月份投稿到现在四个月了还是Under review状态的？给杂志写信也没消息😂😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/02/efd7344eb2f4c381b10c1a9b2acaf549.jpg, createdBy=22da73016, createdName=哈哈这就是学术圈, createdTime=Wed Jun 17 08:00:24 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998626, encodeId=287299862659, content=应邀审稿本国一篇，感觉质量不太高，4，5分水平吧。达不到此刊物水准，正在考虑要不拒掉，又同情本国作者，毕竟工作量不少，可能最终建议大修。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Sun Jul 11 21:27:31 CST 2021, time=2021-07-11, status=1, ipAttribution=)]

2021-11-24 ms4000001342707312

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：RNA结合蛋白;肿瘤
经验分享：oncogene被秒拒。cancer letters一审后建议转投translational oncology。7月初投，8月13给大修，10月14返修回去，11月15日预接受。至今状态未变。

53 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=908092, encodeId=1e679080927e, content=审稿速度:2.0 经验分享：under review快两个月了，变了其次日期，都是under review，唉，不知道什么情况……还是molecular therapy转投过来的……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15ee5343096, createdName=天涯一刀, createdTime=Tue Dec 15 09:14:44 CST 2020, time=2020-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967344, encodeId=4e9396e34445, content=请问一下各位with editor 之后直接Decision in process是不是要被拒了呢？这个过程得多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5b05427874, createdName=ms2000000326068890, createdTime=Thu May 20 23:33:34 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890776, encodeId=9fc9890e769e, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：7月份投的Molecular Therapy ，编辑说研究偏向基因治疗，建议改投姊妹杂志MTNA，于是改投。中间一次小修，今天收到通知接收！比较顺利，做的比较全，机制，在体验证都做了，审稿人比较认可，小修了一些小问题。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/27/c46a23a4fdf73ffb670608d86a933046.jpg, createdBy=cfaa1692461, createdName=SCI hunter , createdTime=Fri Oct 09 12:40:14 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001862, encodeId=8b61100186282, content=一审四个月，建议大修。但是没有审稿人意见，这是什么操作？只有两条主编的意见，让我改改格式和图片。。。。这是大修？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a85e5091452, createdName=145d4029m98暂无昵称, createdTime=Thu Jul 22 23:23:31 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063270, encodeId=398010632e0d7, content=被吉大一院列为水刊了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0b1654103, createdName=wy-liang, createdTime=Sat Oct 23 22:23:01 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073649, encodeId=733910e3649c4, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：RNA结合蛋白;肿瘤 经验分享：oncogene被秒拒。cancer letters一审后建议转投translational oncology。7月初投，8月13给大修，10月14返修回去，11月15日预接受。至今状态未变。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=849f6144073, createdName=ms4000001342707312, createdTime=Wed Nov 24 21:53:41 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806467, encodeId=e20a80646e29, content=with editor40天了！急死了啊！请问大家最近有状态更新吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56d35399259, createdName=生活减法, createdTime=Thu Aug 06 10:37:17 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900023, encodeId=6be9900023fa, content=请问各位大佬，这本杂志一审一般多久啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7042270125, createdName=medscholar_49146604, createdTime=Tue Nov 17 22:54:22 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602390, encodeId=5b5f60239090, content=有没有同仁从今年二月份投稿到现在四个月了还是Under review状态的？给杂志写信也没消息😂😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/02/efd7344eb2f4c381b10c1a9b2acaf549.jpg, createdBy=22da73016, createdName=哈哈这就是学术圈, createdTime=Wed Jun 17 08:00:24 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998626, encodeId=287299862659, content=应邀审稿本国一篇，感觉质量不太高，4，5分水平吧。达不到此刊物水准，正在考虑要不拒掉，又同情本国作者，毕竟工作量不少，可能最终建议大修。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Sun Jul 11 21:27:31 CST 2021, time=2021-07-11, status=1, ipAttribution=)]

2020-08-06 生活减法

with editor40天了！急死了啊！请问大家最近有状态更新吗？

119 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=908092, encodeId=1e679080927e, content=审稿速度:2.0 经验分享：under review快两个月了，变了其次日期，都是under review，唉，不知道什么情况……还是molecular therapy转投过来的……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15ee5343096, createdName=天涯一刀, createdTime=Tue Dec 15 09:14:44 CST 2020, time=2020-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967344, encodeId=4e9396e34445, content=请问一下各位with editor 之后直接Decision in process是不是要被拒了呢？这个过程得多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5b05427874, createdName=ms2000000326068890, createdTime=Thu May 20 23:33:34 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890776, encodeId=9fc9890e769e, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：7月份投的Molecular Therapy ，编辑说研究偏向基因治疗，建议改投姊妹杂志MTNA，于是改投。中间一次小修，今天收到通知接收！比较顺利，做的比较全，机制，在体验证都做了，审稿人比较认可，小修了一些小问题。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/27/c46a23a4fdf73ffb670608d86a933046.jpg, createdBy=cfaa1692461, createdName=SCI hunter , createdTime=Fri Oct 09 12:40:14 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001862, encodeId=8b61100186282, content=一审四个月，建议大修。但是没有审稿人意见，这是什么操作？只有两条主编的意见，让我改改格式和图片。。。。这是大修？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a85e5091452, createdName=145d4029m98暂无昵称, createdTime=Thu Jul 22 23:23:31 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063270, encodeId=398010632e0d7, content=被吉大一院列为水刊了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0b1654103, createdName=wy-liang, createdTime=Sat Oct 23 22:23:01 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073649, encodeId=733910e3649c4, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：RNA结合蛋白;肿瘤 经验分享：oncogene被秒拒。cancer letters一审后建议转投translational oncology。7月初投，8月13给大修，10月14返修回去，11月15日预接受。至今状态未变。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=849f6144073, createdName=ms4000001342707312, createdTime=Wed Nov 24 21:53:41 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806467, encodeId=e20a80646e29, content=with editor40天了！急死了啊！请问大家最近有状态更新吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56d35399259, createdName=生活减法, createdTime=Thu Aug 06 10:37:17 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900023, encodeId=6be9900023fa, content=请问各位大佬，这本杂志一审一般多久啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7042270125, createdName=medscholar_49146604, createdTime=Tue Nov 17 22:54:22 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602390, encodeId=5b5f60239090, content=有没有同仁从今年二月份投稿到现在四个月了还是Under review状态的？给杂志写信也没消息😂😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/02/efd7344eb2f4c381b10c1a9b2acaf549.jpg, createdBy=22da73016, createdName=哈哈这就是学术圈, createdTime=Wed Jun 17 08:00:24 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998626, encodeId=287299862659, content=应邀审稿本国一篇，感觉质量不太高，4，5分水平吧。达不到此刊物水准，正在考虑要不拒掉，又同情本国作者，毕竟工作量不少，可能最终建议大修。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Sun Jul 11 21:27:31 CST 2021, time=2021-07-11, status=1, ipAttribution=)]

2020-11-17 medscholar_49146604

请问各位大佬，这本杂志一审一般多久啊？

88 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=908092, encodeId=1e679080927e, content=审稿速度:2.0 经验分享：under review快两个月了，变了其次日期，都是under review，唉，不知道什么情况……还是molecular therapy转投过来的……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15ee5343096, createdName=天涯一刀, createdTime=Tue Dec 15 09:14:44 CST 2020, time=2020-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967344, encodeId=4e9396e34445, content=请问一下各位with editor 之后直接Decision in process是不是要被拒了呢？这个过程得多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5b05427874, createdName=ms2000000326068890, createdTime=Thu May 20 23:33:34 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890776, encodeId=9fc9890e769e, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：7月份投的Molecular Therapy ，编辑说研究偏向基因治疗，建议改投姊妹杂志MTNA，于是改投。中间一次小修，今天收到通知接收！比较顺利，做的比较全，机制，在体验证都做了，审稿人比较认可，小修了一些小问题。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/27/c46a23a4fdf73ffb670608d86a933046.jpg, createdBy=cfaa1692461, createdName=SCI hunter , createdTime=Fri Oct 09 12:40:14 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001862, encodeId=8b61100186282, content=一审四个月，建议大修。但是没有审稿人意见，这是什么操作？只有两条主编的意见，让我改改格式和图片。。。。这是大修？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a85e5091452, createdName=145d4029m98暂无昵称, createdTime=Thu Jul 22 23:23:31 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063270, encodeId=398010632e0d7, content=被吉大一院列为水刊了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0b1654103, createdName=wy-liang, createdTime=Sat Oct 23 22:23:01 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073649, encodeId=733910e3649c4, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：RNA结合蛋白;肿瘤 经验分享：oncogene被秒拒。cancer letters一审后建议转投translational oncology。7月初投，8月13给大修，10月14返修回去，11月15日预接受。至今状态未变。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=849f6144073, createdName=ms4000001342707312, createdTime=Wed Nov 24 21:53:41 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806467, encodeId=e20a80646e29, content=with editor40天了！急死了啊！请问大家最近有状态更新吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56d35399259, createdName=生活减法, createdTime=Thu Aug 06 10:37:17 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900023, encodeId=6be9900023fa, content=请问各位大佬，这本杂志一审一般多久啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7042270125, createdName=medscholar_49146604, createdTime=Tue Nov 17 22:54:22 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602390, encodeId=5b5f60239090, content=有没有同仁从今年二月份投稿到现在四个月了还是Under review状态的？给杂志写信也没消息😂😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/02/efd7344eb2f4c381b10c1a9b2acaf549.jpg, createdBy=22da73016, createdName=哈哈这就是学术圈, createdTime=Wed Jun 17 08:00:24 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998626, encodeId=287299862659, content=应邀审稿本国一篇，感觉质量不太高，4，5分水平吧。达不到此刊物水准，正在考虑要不拒掉，又同情本国作者，毕竟工作量不少，可能最终建议大修。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Sun Jul 11 21:27:31 CST 2021, time=2021-07-11, status=1, ipAttribution=)]

2020-06-17 哈哈这就是学术圈

有没有同仁从今年二月份投稿到现在四个月了还是Under review状态的？给杂志写信也没消息😂😂

103 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=908092, encodeId=1e679080927e, content=审稿速度:2.0 经验分享：under review快两个月了，变了其次日期，都是under review，唉，不知道什么情况……还是molecular therapy转投过来的……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=17, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15ee5343096, createdName=天涯一刀, createdTime=Tue Dec 15 09:14:44 CST 2020, time=2020-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967344, encodeId=4e9396e34445, content=请问一下各位with editor 之后直接Decision in process是不是要被拒了呢？这个过程得多久呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5b05427874, createdName=ms2000000326068890, createdTime=Thu May 20 23:33:34 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890776, encodeId=9fc9890e769e, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：7月份投的Molecular Therapy ，编辑说研究偏向基因治疗，建议改投姊妹杂志MTNA，于是改投。中间一次小修，今天收到通知接收！比较顺利，做的比较全，机制，在体验证都做了，审稿人比较认可，小修了一些小问题。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=165, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/06/27/c46a23a4fdf73ffb670608d86a933046.jpg, createdBy=cfaa1692461, createdName=SCI hunter , createdTime=Fri Oct 09 12:40:14 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001862, encodeId=8b61100186282, content=一审四个月，建议大修。但是没有审稿人意见，这是什么操作？只有两条主编的意见，让我改改格式和图片。。。。这是大修？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a85e5091452, createdName=145d4029m98暂无昵称, createdTime=Thu Jul 22 23:23:31 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063270, encodeId=398010632e0d7, content=被吉大一院列为水刊了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0b1654103, createdName=wy-liang, createdTime=Sat Oct 23 22:23:01 CST 2021, time=2021-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073649, encodeId=733910e3649c4, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：RNA结合蛋白;肿瘤 经验分享：oncogene被秒拒。cancer letters一审后建议转投translational oncology。7月初投，8月13给大修，10月14返修回去，11月15日预接受。至今状态未变。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=849f6144073, createdName=ms4000001342707312, createdTime=Wed Nov 24 21:53:41 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806467, encodeId=e20a80646e29, content=with editor40天了！急死了啊！请问大家最近有状态更新吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56d35399259, createdName=生活减法, createdTime=Thu Aug 06 10:37:17 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900023, encodeId=6be9900023fa, content=请问各位大佬，这本杂志一审一般多久啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7042270125, createdName=medscholar_49146604, createdTime=Tue Nov 17 22:54:22 CST 2020, time=2020-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602390, encodeId=5b5f60239090, content=有没有同仁从今年二月份投稿到现在四个月了还是Under review状态的？给杂志写信也没消息😂😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/02/efd7344eb2f4c381b10c1a9b2acaf549.jpg, createdBy=22da73016, createdName=哈哈这就是学术圈, createdTime=Wed Jun 17 08:00:24 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998626, encodeId=287299862659, content=应邀审稿本国一篇，感觉质量不太高，4，5分水平吧。达不到此刊物水准，正在考虑要不拒掉，又同情本国作者，毕竟工作量不少，可能最终建议大修。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Sun Jul 11 21:27:31 CST 2021, time=2021-07-11, status=1, ipAttribution=)]

2021-07-11 cindichaw

应邀审稿本国一篇，感觉质量不太高，4，5分水平吧。达不到此刊物水准，正在考虑要不拒掉，又同情本国作者，毕竟工作量不少，可能最终建议大修。

1 6

展开6条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务